Answers are grounded in this paper and cite their sources.
T cells express very high amounts of PD-1 and other co-stimulatory and inhibitory receptors. Here, we address the hypothesis that targeting CTLA-4 or PD-1 and its ligand PD-L1 critically impacts the function of Tfh cells in patients that receive these ICIs, thereby providing a link between ICI treatment and the development of secondary autoimmunity.
No takes yet. Share an insight, caveat, or question.
Baumjohann et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: